ProtaGene

ProtaGene is a world-leading CRO partner offering comprehensive analytical solutions for biologic drugs and cell & gene therapies. Founded in 2001 and headquartered in Göttingen, Germany, the company leverages state-of-the-art technology and deep scientific expertise to support global clients across all development stages, from discovery to market release. Its service portfolio includes advanced characterization, safety testing, lot release, and stability studies, positioning it as a critical enabler for accelerating regulatory submissions and product commercialization. As a private, revenue-generating services firm, ProtaGene operates at the intersection of high-growth therapeutic modalities and stringent analytical requirements.

Integrated analytical service platform for protein biologics and cell & gene therapies, encompassing advanced mass spectrometry, sequencing, cell-based assays, and custom method development for characterization, safety, and release testing.

Competes with large global CROs (e.g., LabCorp, IQVIA, Charles River) that have broad service portfolios, as well as specialized analytical service providers focused on biologics or gene therapy. Differentiation is achieved through deep integrated expertise in both protein and gene analytics, tailored assay development, and a dedicated focus on the entire development lifecycle.